Eli Lilly and Junshi Biosciences have begun a phase 1 trial of a second neutralizing antibody for COVID-19.

The trial led by Junshi in China will evaluate the safety and tolerability of the antibody, JS016, in healthy participants who have not been diagnosed with COVID-19. Eli Lilly also plans to begin a phase 1 trial of the antibody in the U.S. soon. 

The companies last week began a phase 1 trial of a separate COVID-19 antibody, LY-CoV555.